Pharmaceutical composition for combination of piperidinoalkanol-decongestant
Patent 6039974 Issued on March 21, 2000. Estimated Expiration Date: 
July 31, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
July 31, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3806526 3878217 Pharmaceutical compositions and preparing same Preparation of rapidly resorbable glibenclamide Rapidly resorbable glibenclamide Orally administrable form of progesterone Piperidine derivatives Piperidine derivatives 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof 1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof InventorsAssigneeApplicationNo. 127478 filed on 07/31/1998US Classes:424/472, Layered unitary dosage forms424/468, Sustained or differential release type424/474, Coated pills or tablets424/475, Organic coatings514/770, Siliceous or calcareous material (e.g., clay, earth, etc.)514/778, Starch or derivative514/781, Cellulose or derivative514/783, Plant extract or plant material of undetermined constitution514/784, Carboxylic acid or salt thereof514/853DECONGESTANTExaminersPrimary: Spear, James M.Attorney, Agent or FirmForeign Patent References
International ClassesA61K 009/22A61K 009/24 A61K 009/28 AbstractThe present invention provides a pharmaceutical composition in the form of a bilayer tablet comprising,(a) a first discrete zone made with Formulation (A) which comprises, a therapeutically effective decongestant amount of a sympathomimetic drug, or a pharmaceutically acceptable salt thereof, in an amount of about 18% to about 39% by weight of Formulation (A), and a first carrier base material, the first carrier base material comprising a mixture of;(I) carnauba wax in an amount of about 59% to about 81% by weight of Formulation (A); and(ii) a suitable antiadherent in an amount of about 0.25% to about 2.00% by weight of Formulation (A);wherein said first carrier base material provides a sustained release of the sympathomimetic drug; and(b) a second discrete zone made with Formulation (B) which comprises a therapeutically effective antihistaminic amount of a piperidinoalkanol, or a pharmaceutically acceptable salt thereof, in an amount of about 15% to about 30% by weight of Formulation (B) and a second carrier base material, the second carrier base comprising a mixture of;(I) a cellulose diluent in an amount of about 27% to about 73% by weight of Formulation (B);(ii) pregelatinized starch in an amount of about 15% to about 30% by weight of Formulation (B);(iii) a suitable disintegrant in an amount of about 0.25% to about 6.00% by weight of Formulation (B); and(iv) a suitable lubricant in an amount of about 0.25% to about 2.00% by weight of Formulation (B);wherein said second carrier base material provides an immediate release of the piperidinoalkanol or the pharmaceutically acceptable salt thereof.Other References
| |
